IOVANCE BIOTHERAPEUTICS, INC. 8-K

What Happened

• Iovance Biotherapeutics, Inc. held its 2026 Annual Meeting of Stockholders virtually on June 10, 2026; 329,492,680 shares (about 74% of outstanding common stock) were represented. All seven director nominees were elected: Iain Dukes, D. Phil.; Athena Countouriotis, M.D.; Ryan Maynard; Wayne P. Rothbaum; Frederick G. Vogt, Ph.D., J.D.; and Michael Weiser, M.D., Ph.D.
• Shareholders approved several proposals, including a non-binding advisory vote on executive compensation, a one-year frequency for future advisory votes, ratification of Ernst & Young LLP as auditor, an amendment to increase the 2020 Employee Stock Purchase Plan by 1,000,000 shares, and an amendment to increase authorized common shares from 500,000,000 to 650,000,000. Separately, on June 4, 2026, Iovance announced that Australia’s Therapeutic Goods Administration (TGA) approved Amtagvi® for previously treated advanced (metastatic or unresectable) melanoma.

Key Details

• Shares represented at meeting: 329,492,680 (~74% of outstanding).
• Director election vote example (others reported similarly): Iain Dukes — For: 182,990,471; Withheld: 16,322,922; Broker non-votes: 130,179,287. All nominees were elected.
• Authorized common shares increase (Proposal 6): Approved — For: 254,976,692; Against: 71,438,492; Abstain: 3,077,496.
• TGA approval: Amtagvi® approved June 4, 2026 for previously treated advanced (metastatic or unresectable) melanoma; press release attached as Exhibit 99.1 to the filing.

Why It Matters

• Board continuity and ratified auditor: Election of the full slate of directors and ratification of Ernst & Young preserve management and audit continuity, which matters for oversight and financial reporting stability.
• Capital/stock plan flexibility: Approval to increase authorized common shares (from 500M to 650M) and to add 1,000,000 shares to the ESPP gives the company flexibility for future financings, equity compensation, or corporate actions — items investors should monitor for potential dilution.
• Commercial expansion: TGA approval of Amtagvi in Australia formally opens a regulated market for the product in that country, a concrete regulatory milestone that could affect the company’s international rollout and future revenue opportunities.